Physician profile
Jonathan Bloomberg
NPI 1336322924
$3,448.31
in general payments reported to CMS, 2019-2025
27 companies · $783 in 2025
The $783 reported for 2025 was more than what 82% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,725 · 2020: $389 · 2021: $171 · 2022: $210 · 2023: $112 · 2024: $57.34 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.12 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.62 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $312.10 | 2019-2025 | Rexulti |
| Allergan, INC. | $299.92 | 2019-2020 | |
| Lundbeck LLC | $263.24 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $223.34 | 2019-2025 | Spravato |
| Neos Therapeutics, LP | $216.27 | 2019-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $173.29 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $161.22 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $149.84 | 2019-2025 | Relexxii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.57 | 2023-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $139.35 | 2019 | |
| Corium, LLC | $124.86 | 2023-2025 | Azstarys |
| Shire North American Group INC | $121.22 | 2019 | |
| Adlon Therapeutics L.P. | $114.78 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $109.21 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $91.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $81.88 | 2024-2025 | Cobenfy |
| Harmony Biosciences LLC | $69.86 | 2021-2024 | |
| Tris Pharma INC | $61.32 | 2019-2025 | Onyda Xr |
| Alkermes, INC. | $53.05 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $48.22 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $44.07 | 2021-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $22.52 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $18.08 | 2025 | Auvelity |
| Neuronetics, INC. | $14.56 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $13.44 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.86 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bloomberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.